Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Robert Miller +44 (0)1865 582 690
info@scancell.co.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)
Back

SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study)

Recruiting

Open to: ALL

Age: 18.0 - N/A

London Manchester Northwood Southampton Cambridge Preston London Leeds London Sheffield Cardiff Oxford Plymouth Taunton Nottingham

Medical Conditions

Melanoma

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The purpose of this study is to find out if two new treatment cancer vaccines called SCIB1 and iSCIB1+ can be used safely when added to nivolumab (Opdivo) with ipilimumab (Yervoy), or SCIB1 with pembrolizumab (Keytruda). Pembrolizumab or nivolumab with ipilimumab are standard treatments approved for patients with advanced melanoma (skin cancer).

The study will also look to see if SCIB1 or iSCIB1+ can increase the likelihood that melanoma patients will respond to the standard treatments, and also if SCIB1 and iSCIB1+ can help to make those responses last longer. SCIB1 and iSCIB1+ are considered experimental. SCIB1 has been given to melanoma patients in an earlier study. It was generally well-tolerated, and researchers saw some signs that it may help to stimulate the immune system, which is a way in which the body can fight the cancer. iSCIB1+ is similar to SCIB1 but might benefit more patients with melanoma.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Aug 2019 Jan 2027

INTERVENTIONAL

Intervention Type : BIOLOGICAL
Intervention Description : Participants receive up to 11 doses of either SCIB1 or iSCIB1+ up to 85 weeks, in combination with nivolumab with ipilimumab or SCIB1 with pembrolizumab.

Nivolumab with ipilimumab or pembrolizumab treatment will be started 1 week after the first dose of SCIB1 or iSCIB1+ and given as per standard treatment.

Intervention Arm Group : SCIB1 or iSCIB1+;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • Royal Free London NHS Foundation Trust
    London
  • The Christie NHS Foundation Trust
    Manchester
  • East and North Hertfordshire NHS Trust
    Northwood
  • University Hospital Southampton NHS Foundation Trust
    Southampton
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge
  • Lancashire Teaching Hospitals NHS Foundation Trust
    Preston
  • The Royal Marsden NHS Foundation Trust
    London
  • The Leeds Teaching Hospitals NHS Trust
    Leeds
  • Guy's & St Thomas' NHS Foundation Trust
    London
  • Sheffield Teaching Hospital NHS Foundation Trust
    Sheffield
  • Velindre University NHS Trust
    Cardiff
  • Oxford University Hospital NHS Foundation Trust
    Oxford
  • University Hospital Plymouth NHS trust
    Plymouth
  • Somerset NHS Foundation Trust
    Taunton
  • Nottingham University Hospitals NHS Trust
    Nottingham

Robert Miller +44 (0)1865 582 690
info@scancell.co.uk



The study is sponsored by Scancell Ltd



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT04079166
Last updated 01 April 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top